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The benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-one core was discovered as a novel ERK5 (also known as
MAPK7 and BMK1) inhibitor scaffold, previously. Further structureeactivity relationship studies of this
scaffold led to the discovery of ERK5-IN-1 (26) as the most selective and potent ERK5 inhibitor reported
to date. 26 potently inhibits ERK5 biochemically with an IC50 of 0.162  0.006 mM and in cells with a
cellular EC50 for inhibiting epidermal growth factor induced ERK5 autophosphorylation of
0.09  0.03 mM. Furthermore, 26 displays excellent selectivity over other kinases with a KINOMEscan
selectivity score (S10) of 0.007, and exhibits exceptional bioavailability (F%) of 90% in mice. 26 will serve
as a valuable tool compound to investigate the ERK5 signaling pathway and as a starting point for
developing an ERK5 directed therapeutic agent.
 2013 The Authors. Published by Elsevier Masson SAS.Open access under CC BY license.1. Introduction
Extracelluar-signal-regulated kinase 5 (ERK5) (also known as
MAPK7 and big MAP kinase 1 (BMK1)) is the least well studied
member of mitogen-activated protein kinases (MAPKs) family [1,2]., N,N-diisopropylethylamine;
N,N-dimethylacetamide; EGF,
egulated kinase 5; HCC, he-
nase 2; MAPK, mitogen-acti-
kinase 7; MEK5, MAP kinase
adium-(0); PLK, polo-like ki-
ribosomal S6 kinase; SAR,
exylphosphino-20 ,40 ,60-triiso-
iology, Dana-Farber Cancer
, SGM 628, Boston, MA 02115,
(N.S. Gray).
r Masson SAS. Open access under CC Recent data pointing to a potential role of ERK5 in pathological
conditions such as cancer and tumor angiogenesis has greatly
increased interest in this signaling pathway [3]. For example, in
breast cancer, ERK5 expression is up-regulated by constitutive
activation of signal transducer and activator of transcription 3
(STAT3) [4]. In prostate cancer, ERK5 is over-expressed and corre-
lates with the presence of bone metastases and aggressiveness of
the disease [5,6]. Additionally, ERK5 is a target for gene ampliﬁca-
tion at 17p11 in hepatocellular carcinoma (HCC), an ampliﬁcation
detected in approximately 50% of primary HCC tumors [7]. More
importantly, reduction of ERK5 expression or signaling signiﬁcantly
inhibited the motility and invasive capability of PC3 cells [8]. And
ERK5 protein levels are also regulated by tumor-suppressive
microRNAs (miRNAs), including miR-143 and miR-145 [9e11].
These observations suggest that small molecule ERK5 inhibitors
may serve as potential therapeutic agents for the treatment of
ERK5-dependent cancer and other diseases.BY license.
Fig. 2. Development of ERK5 inhibitor (XMD8-92) and LRRK2 inhibitor (LRRK2-IN-1)
from pyrimido-diazepine.
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ERK5, the development of selective ERK5 inhibitors has lagged
behind. Since the cloning of ERK5 in 1995 [12,13], there have been
only two reported oxindole derived inhibitors which are dual in-
hibitors of ERK5 and its upstream kinase MEK5: BIX02188 and
BIX02189 (Fig. 1) [14]. In an effort to discover small molecules that
can selectively inhibit ERK5 kinase activity, we designed and syn-
thesized a collection of approximately ﬁfty analogs derived from
the 2-amino pyrido[2,3-d]pyrimidine template. The pyrido[2,3-d]
pyrimidine core can be classiﬁed as a privileged ATP-site targeting
scaffold as is exempliﬁed by compounds such as: BI-2536, a se-
lective polo-like kinase family (PLK1, PLK2 and PLK3) inhibitor
[15,16] and BI-D1870, an inhibitor of RSK [17] (Fig. 2). Kinome-wide
selectivity proﬁling of this collection of 2-amino pyrido[2,3-d]py-
rimidines using the KINOMEscan approach [18] resulted in the
discovery of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones as
inhibitors of ERK5. In our previous study (Fig. 2) [19e21], we re-
ported the identiﬁcation and preliminary structureeactivity rela-
tionship (SAR) of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-one
XMD8-92 (11) as a selective and moderately potent cellular and
in vivo ERK5 inhibitor [20]. Using this inhibitor, 11, we determined
that ERK5 inhibits the tumor suppressor activity of cellular pro-
myelocytic leukemia protein (PML) and demonstrated efﬁcacy and
tolerability of the inhibitor against two tumor xenografts providing
preliminary support for further exploration of ERK5 inhibitors as
anti-cancer agents [20]. Later, LRRK2-IN-1 (15), a new analog
derived from this scaffold, was identiﬁed as a leucine rich repeat
kinase 2 (LRRK2) inhibitor with potent activity and a good selec-
tivity proﬁle using a “compound centric” kinase proﬁling strategy
[21]. Compound 15 also exhibited a cellular EC50 for inhibiting
epidermal growth factor (EGF) induced ERK5 autophosphorylation
of 0.16 mM. These results demonstrated that the benzo[e]pyrimido-
[5,4-b]diazepine-6(11H)-one scaffold is well suited to developing
inhibitors of both ERK5 and LRRK2 and we were curious to explore
modiﬁcations to the scaffold that could impart selectivity between
these two targets and across the kinome in general. In this article,
we describe biochemical and cellular analysis of the benzo[e]pyr-
imido-[5,4-b]diazepine-6(11H)-one scaffold with respect to their
activity against ERK5 and LRRK2. This effort culminated in the
discovery of ERK5-IN-1 (26) as the most potent and selective ERK5
inhibitor reported to date.
2. Results and discussion
2.1. Chemistry
An efﬁcient four-step synthetic route was developed to enable
the synthesis of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.Fig. 1. Dual inhibitors oCompounds 5e18 and 20e24 were synthesized as described pre-
viously [19]. The synthesis of 25 using a modiﬁed synthetic pro-
cedure is outlined in Scheme 1. First, 2,4-dichloro-5-
nitropyrimidine was reacted with N-cyclopentylanthranilic ethyl
ester under acidic conditions using 4 N hydrochloric acid in dioxane
at 60 C to give the amination product 2 in good yield. We observed
that the yield of the substitution reaction under acidic conditions is
higher than that obtained under basic condition which we used
previously [19]. The substitution reaction was followed by iron-
mediated reduction of 2 and in situ cyclization in acetic acid at
60 C to afford the 7-member lactam intermediate 3 in good yield.
Compound 25 was obtained via methylation of the lactam of 3
followed by palladium mediated amination of 4 with (4-amino-3-
methoxyphenyl) (4-(4-methylpiperazin-1-yl)piperidin-1-yl)metha
none.2.2. SAR of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones for
ERK5 and LRRK2
The SAR of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones was
explored with respect to ERK5 and LRRK2 using a combination of
biochemical and cellular readouts. We used a cellular assay that
measures the ability of compounds to inhibit the autophosphor-
ylation of ERK5 in HeLa cells in response to epidermal growth factor
(EGF) stimulation. HeLa cells were serum starved overnight fol-
lowed by treatment with inhibitors for 1 h. Cells were then stim-
ulated with epidermal growth factor (EGF, 20 ng/mL) for 17 min,
and ERK5 activation was detected by mobility retardation [22].
Here we also used a newly developed radiochemical assay tof ERK5 and MEK5.
a Reagents and conditions: (a) 4 N HCl in Dioxane, Dioxane, 60 ˚C, 79% yield; (b) Fe/HOAc, 60 
˚C, 84% yield; (c) MeI/NaH, DMA, 0 ˚C, 83% yield; (d) X-Phos (9% mol), Pd2(dba)3 (6% mol), 
K2CO3 (3.0 eq.), t-BuOH, 100 ˚C, 57% yield.
Scheme 1. Synthesis of 2-Amino-11-cyclopentyl-5-methyl-5H-benzo[e]pyrimido[5,4-b][1,4] diazepin-6(11H)-one.a
aReagents and conditions: (a) 4 N HCl in Dioxane, Dioxane, 60 C, 79% yield; (b) Fe/HOAc, 60 C, 84% yield; (c) MeI/NaH, DMA, 0 C, 83% yield; (d) X-Phos (9% mol), Pd2(dba)3 (6%
mol), K2CO3 (3.0 eq.), t-BuOH, 100 C, 57% yield.
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the PIMtide peptide as substrates. Compounds were tested for their
ability to inhibit the incorporation of 32P into the PIMtide substrate.
We assessed inhibition of LRRK2 by measuring the IC50 values of
the inhibitors against recombinant LRRK2 [G2019S], a naturally
occurring activating mutation linked to Parkinsons’ disease [23],
using the Adapta kinase assay format (Invitrogen) as readouts
(Tables 1 and 2) [24]. Our cellular assay for LRRK2 measures the
ability of compounds to inhibit LRRK2-dependent phosphorylation
of Ser910 and Ser935 in stably transformed HEK293 cells as
described previously [21,25].
We ﬁrst explored the 2-amino moiety of this scaffold by intro-
ducing different anilines and alkyl amines. Introduction of 2-
methoxy-4-(4-methylpiperazin-1-yl)aniline, 2-methoxy-4-(4-
hydroxypiperidin-1-yl)aniline, 2-methoxy-4-morpholinoaniline
and 4-sulfonamideaniline resulted in compounds 5e8. These
compounds all exhibited potent inhibition of ERK5 with cellular
EC50 values of 0.19e0.31 mM and enzymatic IC50 values of 0.09e
0.30 mM and of LRRK2[G2019S] with enzymatic IC50 values of
0.007e0.031 mM (Table 1). In contrast introduction of a 2-(1H-
imidazol-2-yl)ethanamine or 1-methylpiperidin-4-amine as in
compounds 9 and 10 resulted in complete loss of activity against
both ERK5 and LRRK2[G2019S]. These results suggested that the
phenyl ring of the 2-amino moiety may possess important in-
teractions with both kinases. We investigated the effect of ortho-
substitution of the aniline by introducing a 2-ethoxy (11) and 2-
isoproxy (12). Compound 11 possessed similar activity against
ERK5 comparing to 6 and exhibited slightly decreased activity
against LRRK2[G2019S]. Compound 12 which contains the 2-
isoproxyl substituent exhibited a dramatic decrease in activity for
both kinases. These observations combined with published SAR for
a pan Aurora inhibitor from the same scaffold [26] and the ERK5
inhibitor XMD8-92 (11) [19] suggest that substitution of the ortho-
position of the 2-aniline moiety of 5 with larger substituents is
slightly better tolerated for ERK5 than for LRRK2. Introduction of
various amides at the 4-position of 2-methoxylaniline resulted in
compounds 13e15. Compounds 13 and 14 maintained similaractivity against ERK5 while 15 exhibited the best activity within
this set of compounds. Meanwhile compounds 13e15 exhibited
IC50 values in the single digit nanomolar range against LRRK2
[G2019S]. In sum, the amide functional group at the 4-position of
the 2-anilino moiety is favorable for both ERK5 and LRRK2.
We next investigated the effects of modiﬁcation to the N-sub-
stituent (R2) of the lactam, to the N-substituent (R3) of the an-
thranilic acid and to the aryl ring (R4) (Table 2). Compound 16
containing an unsubstituted lactam amide exhibited a 4-fold
decrease in activities for both ERK5 and LRRK2[G2019S] kinases,
which indicated the methyl substitution of the lactam is preferred.
N-substituents (R3) of increasing size from methyl (5), ethyl (17),
isopropyl (18), to cyclopentyl (19) all maintained similar ERK5
inhibitory activity while inhibition of LRRK2[G2019S] was dimin-
ished. This series resulted in the important insight that ERK5 can
tolerate larger R3 groups relative to LRRK2[G2019S] thereby
providing a method to achieve selectivity for ERK5. For example,
compound 19 containing a N-cyclopentyl at R3 exhibited a 30-fold
decrease in IC50 (0.781 mM) for LRRK2[G2019S] relative to the
methylated compound 5. There appears to be limited tolerance for
substitution on the aryl ring of anthranilic acid, as the 4-ﬂuoro, 5-
chloro, 4-chloro, and 5-methyl analogs (20, 21, 22, and 23 respec-
tively) all exhibited a dramatic loss in activity for both ERK5 and
LRRK2. Compound 24 with the indoline-7-carboxylic linkage (R6)
exhibited similar LRRK2 activity compared to LRRK2-IN-1 (15),
while the ERK5 activity was decreased. However, the use of 24 at a
concentration of 1 mM in cellular assays is still likely to inhibit both
targets. Compound 25 having the combination of 2-methoxy-4-(4-
methylpiperazin-1-yl)piperidin-1-carbonyl-aniline (R2) and N-
cyclopentyl (R3) exhibited a cellular EC50 of 0.08  0.02 mM and an
enzymatic IC50 of 0.082 0.009 mM against ERK5 and an enzymatic
IC50 of 0.061 mM for LRRK2[G2012S] which is more than a 10-fold
decrease in activity against this target when compared to LRRK2-
IN-1 (15). Further elaboration to combine the ortho-ethoxy sub-
stitution and the cyclopentyl at R3 resulted in the synthesis of 26
which possesses a cellular EC50 of 0.09 0.03 mM and an enzymatic
IC50 of 0.162  0.006 mM against ERK5 and enzymatic IC50 of
Table 1
SAR of 2-amino moiety for ERK5 and LRRK2
Compound ID R1 Cellular EC50 (ERK5, mM)a Enzymatic IC50 (ERK5, mM)b Enzymatic IC50
(LRRK2[G2019S], mM)c
5 0.19  0.04 0.087  0.007 0.026
6 0.24  0.04 0.297  0.014 0.017
7 0.26  0.03 0.233  0.019 0.031
8 0.31  0.06 0.171  0.016 0.07
9 4.68  0.52 1.724  0.221 2.37
10 4.11  0.59 1.253  0.151 >10
11 0.24  0.04 0.364  0.058 0.059
12 >0.5 1.530  0.172 0.256
13 0.24  0.03 0.140  0.009 0.005
14 0.32  0.05 0.338  0.018 0.008
15 0.16  0.04 0.114  0.011 0.004
a The required concentration for inhibiting 50% of EGF-stimulated autophosphorylation of ERK5 in HeLa cells.
b The required concentration for inhibiting 50% of enzymatic activity of ERK5 using an in vitro assay.
c The required concentration for inhibiting 50% of enzymatic activity of LRRK2[G2019S] using an in vitro assay.
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most potent and selective ERK5 inhibitor that we have been able to
discover from this chemical series. The ability of the benzo[e]pyr-
imido-[5,4-b]diazepine-6(11H)-ones to inhibit ERK5 activity in vitro
correlated well with their ability to inhibit ERK5 autophosphor-
ylation in cells (see the scatter plot in Supplemental Fig. S1).
The SAR exploration of the benzo[e]pyrimido-[5,4-b]diazepine-
6(11H)-one scaffold led to the discovery of the relatively LRRK2
selective inhibitor 24 and ERK5 selective inhibitor 26. The struc-
tural features of N-methyl substitution of the lactam (R2), the 2-
ethoxy group of the 4-amide substituted aniline, N-cyclopentyl
substitution (R3) of the anthranilic acid and no substituent (R4 ¼ H)on the aryl ring of anthranilic acid were essential to achieve potent
cellular inhibitory activity against ERK5 and high speciﬁcity.
2.3. Cellular LRRK2 inhibitory effect of compound 24 and 26
We examined the abilities of compounds 24 and 26 to inhibit
LRRK2 in a cellular context. As there are no validated direct phos-
phorylation substrates of LRRK2, we monitored phosphorylation of
Ser910 and Ser935, two residues whose phosphorylation is known
to be dependent upon LRRK2 kinase activity [25] (Fig. 3). Com-
pound 24 induced a dose-dependent inhibition of Ser910 and
Ser935 phosphorylation in both wild-type LRRK2 and LRRK2
Table 2
SAR of substituents of anthranilic acid moiety for ERK5 and LRRK2.
Compound ID R Cellular EC50 (ERK5, mM)a Enzymatic IC50 (ERK5, mM)b Enzymatic IC50
(LRRK2[G2019S], mM)c
5 R2, R3 ¼ Me, Me 0.19  0.04 0.087  0.007 0.026
16 H, Me >1.0 1.450  0.210 0.091
17 Me, Et 0.20  0.04 0.066  0.007 0.052
18 Me, i-Pr 0.23  0.03 0.098  0.012 0.36
19 Me, cyclopentyl 0.20  0.04 0.146  0.018 0.781
20 R4 ¼ 4-F 1.32  0.22 0.873  0.060 0.439
21 5-Cl 1.24  0.24 1.130  0.160 1.07
22 4-Cl 11.38  2.04 5.090  0.052 >10
23 5-Me 3.10  0.62 2.460  0.260 0.493
24
R5, R6 = Me, 
0.26  0.04 0.199  0.012 0.005
25
Me, 
0.08  0.02 0.082  0.009 0.061
26
Et, 
0.09  0.03 0.162  0.006 0.339
a The required concentration for inhibiting 50% of EGF-stimulated autophosphorylation of ERK5 in HeLa cells.
b The required concentration for inhibiting 50% of enzymatic activity of ERK5 using an in vitro assay.
c The required concentration for inhibiting 50% of enzymatic activity of LRRK2[G2019S] using an in vitro assay.
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reduction on the level of phosphorylation of residues Ser910 and
Ser935 was observed at 1e3 mM of 24 for wild-type LRRK2 and at
slightly lower doses for LRRK2[G2019S] (Fig. 3a), which is compa-
rable to the potency exhibited by LRRK2-IN-1 [21]. Compound 24
had no effect on the phosphorylation of Ser910 and Ser935 at a
concentration of up to 3 mM in the drug-resistant LRRK2
[G2019Sþ A2016T] and LRRK2[A2016T]mutants (Fig. 3a), revealing
that 24 has the same activity proﬁle as LRRK2-IN-1 [21]. Consistent
with the biochemical results, compound 26 did not show any
inhibitory effect against LRRK2 at a concentration of up to 3 mM in
this cellular context (Fig. 3b).
We next examined the effects of compounds 24 and 26 on
endogenously expressed LRRK2 in human lymphoblastoid cells
derived from a control and Parkinson’s disease patient homozygous
for the LRRK2[G2019S] mutation (Fig. 4). We found that increasing
doses of 24 led to similar reduction on the levels of phosphorylation
of endogenous LRKK2 at Ser910 and Ser935, as was observed in
HEK293 cells stably expressing wild-type LRRK2 or LRRK2[G2019S]
(compare Figs. 3a to 4a). Moreover, 24was alsomore potent against
LRRK2[G2019S] mutant than wild type LRRK2, which is consistent
with the trend we observed in HEK293 cells. Similarly, compound26 did not show inhibitory effects on endogenous LRRK2 (compare
Figs. 3b to 4b). Taken together, compound 24 is as potent LRRK2
inhibitor as LRRK2-IN-1 and worked both in vitro and in cells and
with improved selectivity towards LRRK2. Compound 26 is an ERK5
speciﬁc inhibitor, which has at least 30-fold cellular selectivity for
ERK5 relative to LRRK2 and should not inhibit LRRK2 when used at
1 mM concentrations.
The pharmacokinetic properties of 26 were also evaluated
following intravenous and oral delivery in mice. This study
demonstrated that 26 exhibits favorable pharmacokinetic proper-
ties with a T1/2 of 8.2 h, AUC of 15745 h*ng/mL and %F of 90
(Table 3).
2.4. Kinase selectivity analysis of compounds 24, 25 and 26
We assessed the selectivity of members of this scaffold using the
KINOMEscan methodology across a near comprehensive panel of
442 kinases [18,27]. Compounds 24, 25 and 26 were screened at a
concentration of 10 mMwhich revealed a highly selective proﬁle for
this inhibitor class (see data in the Supplementary Material).
Compound 26, which contains an ortho-ethoxy aniline demon-
strated outstanding selectivity with a KINOMEscan selectivity score
Fig. 3. Compound 24 inhibits LRRK2 in cells, but 26 not. a) HEK293 cells stably expressing wild-type GFP-LRRK2, GFP-LRRK2[G2019S], GFP-LRRK2[G2019S þ A2016T], and GFP-
LRRK2[A2016T] were treated with DMSO or increasing concentrations of compound 24 for 90 min. Cell lysates were subjected to immunoblotting for detection of LRRK2 phos-
phorylated at Ser910 and Ser935 and for total LRRK2. b) As in a) except 26 was used at the indicated concentration.
Fig. 4. Compound 24 effectively inhibits endogenously expressed LRRK2, but compound 26 not. Endogenous LRRK2 from EBV immortalized human lymphoblastoid cells from a
control subject and a Parkinson’s disease patient homozygous for the LRRK2[G2019S] mutation. After treatment of the cells with DMSO or the indicated concentration of compound
24 (or 26) for 90 min, cell lysates were subjected to immunoblot analysis with the puriﬁed indicated antibody for western analysis. Immunoblots were performed in duplicate, and
results were representative of at least two independent experiments.
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Table 3
Pharmacokinetic parameters of 26.a
Compound Route Dose (mg/kg) Tmax (H) Cmax (ng/mL) AUC0N (h ng/mL) T1/2 (hr) CL (mL/min/Kg) Vss (L/Kg) F (%)
26 IV 1 e 439 1743.83 8.2 8.64 4.67 e
PO 10 4.0 1142.77 15745.48 0 e e 90
a IV ¼ intravenous injection, PO ¼ oral delivery, Tmax ¼ time of maximum plasma concentration, Cmax ¼ maximum plasma concentration, AUC ¼ area under the curve
(measure of exposure), T1/2 ¼ half life, CL ¼ plasma clearance, Vss ¼ volume of distribution, F ¼ oral bioavailability.
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cortin and CaM kinase-like 2 (DCAMKL2) and polo-like kinase 4
(PLK4) were detected. Compound 25 containing a ortho-methoxy
aniline exhibited a S10 of 0.018 (8/442). These results revealed that
the ortho-substituent could serve as a selectivity handle. Compared
with our previously reported ERK5 inhibitor, XMD8-92 (11,
S10 ¼ 0.012, 5/402) [21], compound 26 represents a further
improvement in selectivity. Compound 24 exhibited the same
KINOMEscan selectivity score of S10 of 0.036 (16/442) as that of our
previous LRRK2 inhibitor (LRRK2-IN-1) [21], while being more se-
lective for LRRK2 relative to ERK5. Compounds 25 and 26were also
proﬁled against selected panels of kinases in HeLa and PC3 cell
lysates using a chemical proteomics approach, KiNativ [28]. These
results revealed that only ERK5 was inhibited with higher than 90%
target occupancy at a concentration of 10 mM for both 25 and 26,
which further conﬁrmed their highly selective proﬁles (Please see
Supplementary proﬁling data for details).
To better understand the SAR for LRRK2, we performed a mo-
lecular modeling study using Glide [29]based upon the recently
reported crystal structure of Roco kinase (PDB accession code: 4F1T
[30]) (Fig. 5). This model allows explanation of some of the SAR that
we observed. Overall 26 is predicted to bind to LRRK2 in a manner
analogous to what has been observed for a structural analog, Mps1-
IN-2, bound to TTK [31]: The tricyclic core of the compound curves
around Leu2001 in the base of the ATP binding site, forming two
hydrogen bonds with the hinge region at Ala1950, while the
piperidin-piperazine points towards the solvent exposed region
(Fig. 5A). The cyclopentyl group points towards the glycine rich
loop, against Leu1885, and would appear to force the tricyclic ring
towards the base of the ATP binding site, making contact with
Ala2016. These observations are consistent with the SAR results of
decreased LRRK2 afﬁnity with increasing size up to cyclopentyl (5,
17, 18, 19) (Fig. 5B) of the anthranilic acid N-substituent. The same
contacts with Ala2016 and nearby residues would explain why
substitution of the anthranilic acid (20, 21, 22, and 23) results in
weaker binding. The unfavorable interaction between the ortho-
substituent of the aniline with Leu1949 increases as the substituent
goes frommethoxy to ethoxy to isopropoxyl (6,11, and 12) (Fig. 5C),
which resulted in decreased afﬁnity for LRRK2. These key active site
residues of LRRK2 are either conserved in ERK5 (Leu1949, Leu2001)Fig. 5. Docking model of 26 bound to LRRK2 from three different viewing angles. The N-term
shown in yellow. (For interpretation of the references to colour in this ﬁgure legend, the reor conservatively substituted (Leu1885, Ala2016, Met1947). Our
recently determined co-crystal structure of ERK5 with 25 also
conﬁrms both the binding model for 26 with ERK5 and the
observed SAR trends [32].
3. Conclusions
The new chemo-type of benzo[e]pyrimido-[5,4-b]diazepine-
6(11H)-one represents a privileged scaffold for developing ERK5
and LRRK2 kinase inhibitors. A comprehensive SAR exploration led
to the identiﬁcation of the key structural features required to
separate the SAR of this scaffold between ERK5 and LRRK2. Com-
pound 24 is as potent a LRRK2 inhibitor as LRRK2-IN-1 with
improved selectivity for LRRK2 relative to ERK5 that also possesses
activity in both in vitro and cellular assays. Compound 26 repre-
sents the most selective and potent ERK5 inhibitor we have
developed so far. Given the outstanding speciﬁcity, excellent
cellular efﬁcacy and favorable pharmacokinetic properties, 26
should serve as a versatile tool to further probe ERK5 biology. The
benzo[e]pyrimido-[5,4-b]diaze pine-6(11H)-ones scaffold repre-
sents a ‘priviledged’ template for kinase inhibition due to its ability
to be engineered to possess excellent kinase selectivity, favorable
pharmacokinetic parameters [20,21], and efﬁcacy in xenograft tu-
mor models [20].
4. Experimental protocols
4.1. Chemistry general procedures
Unless otherwise noted, reagents and solvents were obtained
from commercial suppliers and were used without further puriﬁ-
cation. 1H NMR spectra were recorded on 600 MHz (Varian AS600),
and chemical shifts are reported in parts per million (ppm, d)
downﬁeld from tetramethylsilane (TMS). Coupling constants (J) are
reported in Hz. Spin multiplicities are described as s (singlet), brs
(broad singlet), t (triplet), q (quartet), and m (multiplet). Mass
spectra were obtained on a Waters Micromass ZQ instrument.
Preparative HPLC was performed on a Waters Symmetry C18 col-
umn (19  50 mm, 5 mM) using a gradient of 5e95% acetonitrile in
water containing 0.05% triﬂuoroacetic acid (TFA) over 8 mininal lobe of the LRRK2 model is shown in pink, and the C-terminal lobe in green. 26 is
ader is referred to the web version of this article.)
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compounds were in all cases greater than 95%, as determined by
reverse-phase HPLC analysis.
4.2. Synthesis of 11-cyclopentyl-2-((2-methoxy-4-(4-(4-
methylpiperazin-1-yl)piperidine-1-carbonyl)phenyl)amino)-5-
methyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one (25)
A mixture of ethyl 2-(cyclopentylamino)benzoate (1.40 g,
6.0 mmol), 4 N HCl in dioxane solution (2.25mL, 9.0mmol) and 2,4-
dichloro-5-nitropyrimidine (1.74 g, 9.0 mmol) in dioxane (40 mL)
was heated at 60 C for 90 h. After the reaction was complete as
monitoredby thin layer chromatography (TLC), the reaction solution
was concentrated and the residue was puriﬁed by silica-gel column
chromatography with ethyl acetate and hexane (1/20, v/v) to give
the amination product 2 (1.84 g, 79%). MS (ESI)m/z 391 (M þ H)þ.
A mixture of compound 2 (1.79 g, 4.59 mmol) and iron power
(2.57 g, 45.9 mmol) in acetic acid (80 mL) was heated at 60 C for
9 h. After the reactionwas complete as monitored by reverse phase
analytical liquid-chromatography electrospray mass spectrometry
(LC-MS), the solvent was removed in vacuo. The resulting residue
was poured into ice-water which resulted in a solid precipitate that
was collected by ﬁltration, washed with water and air dried to give
the intermediate 3 (1.21 g, 84%). 1H NMR (600 MHz, DMSO-d6)
d 10.48 (s, 1H), 8.18 (s, 1H), 7.57 (d, J ¼ 7.2 Hz, 1H), 7.50 (s, 1H), 7.30
(d, J ¼ 7.2 Hz, 1H), 7.17 (s, 1H), 4.61 (brs, 1H), 2.30e1.90 (m, 2H),
1.70e1.40 (m, 4H), 1.38e1.20 (m, 2H). MS (ESI) m/z 315 (M þ H)þ.
To a stirred suspension of compound 3 (314 mg, 1.0 mmol) and
MeI (0.13mL, 2.0 mmol) in dimethyl acetamide (DMA,10.0 mL) was
added NaH (80mg, 60% suspension inmineral oil) at10 C and the
reaction was gradually warmed to 0 C. After the reaction was
complete asmonitored by LCeMS, the solutionwas poured into ice-
water which resulted in a solid precipitate. The precipitate was
collected by ﬁltration, washed with water and air dried to give the
intermediate 4 (273 mg, 83%). 1H NMR (600 MHz, DMSO-d6) d 8.64
(s, 1H), 7.58 (dd, J ¼ 1.8, 7.8 Hz, 1H), 7.49 (t, J ¼ 7.8 Hz, 1H), 7.33 (d,
J ¼ 8.4 Hz, 1H), 7.19 (t, J ¼ 7.2 Hz, 1H), 4.68e4.64 (m, 1H), 3.44 (s,
3H), 2.28e2.20 (m,1H), 2.10e2.02 (m,1H), 1.64e1.54 (m, 4H), 1.50e
1.34 (m, 2H). MS (ESI) m/z 329 (M þ H)þ.
A mixture of 4 (33 mg, 0.1 mmol), (4-amino-3-
methoxyphenyl)(4-(4-methylpiperazin-1-yl)piperidin-1-yl)meth-
anone (33 mg, 0.1 mmol), X-Phos (4.3 mg), Pd2(dba)3 (5.5 mg) and
K2CO3 (41.5 mg, 0.3 mmol) in 1.2 mL of t-BuOH was purged with
Argon. The resulting mixture in a seal tube was heated at 100 C
until the reaction was complete as monitored by LC-MS. Then the
reaction was ﬁltered through Celite and eluted with dichloro-
methane. The dichloromethane was removed in vacuo and the
resulting crude product was puriﬁed by reverse-phase prep-HPLC
using awater (0.05% TFA)/acetonitrile (0.05% TFA) gradient to afford
the title compound 25 (35.3 mg, 57%). 1H NMR (400 MHz, DMSO-
d6) d 8.44 (s, 1H), 8.20 (d, J ¼ 8.0 Hz, 1H), 8.14 (s, 1H), 7.56 (d,
J ¼ 7.8 Hz, 1H), 7.45 (t, J ¼ 7.7 Hz, 1H), 7.28 (d, J ¼ 8.2 Hz, 1H), 7.15 (t,
J ¼ 7.5 Hz, 1H), 7.03 (s, 1H), 7.00 (d, J ¼ 8.2 Hz, 1H), 4.69e4.64 (m,
1H), 3.86 (s, 3H), 3.42 (s, 3H), 3.32 (d, J ¼ 0.7 Hz, 7H), 2.9e3.1 (m,
6H), 2.75 (s, 3H), 2.28 (m, 1H), 2.07 (m, 1H), 1.75 (br, 2H), 1.60e1.34
(m, 8H); 13C NMR (100 MHz, DMSO-d6) d 169.2, 167.7, 164.3, 158.2,
156.2,152.7,149.5,148.7,132.3,131.3,130.3,128.7,124.7,123.7,121.6,
119.7, 119.2, 110.2, 61.0, 57.1, 56.5, 53.4, 46.3, 42.6, 37.2, 33.1, 32.2,
24.6, 24.5. MS (ESI) m/z 625 (M þ H)þ, HRMS (ESI) m/z calc.
625.3615, measured 625.3633 (M þ H)þ.
4.3. ERK5 autophosphorylation assay [22]
HeLa cells were serum starved overnight followed by treatment
with inhibitors for 1 h. Cells were then stimulated with EGF (20 ng/mL) for 17 min and harvested in RIPA buffer (1 PBS, 1% NP40, 0.5%
sodium deoxycholate, 0.1% SDS, 0.1 mg/ml PMSF and 1 mM sodium
orthovanadate). Proteins from total cell lysates were resolved by 6%
sodium dodecyl sulfate (SDS)-poly-acrylamide gel electrophoresis
(PAGE), transferred to nitrocellulose membrane, blocked in 5%
nonfat milk, and blotted with anti-ERK5 antibody.
4.4. Baculovirus expression of active ERK5 and puriﬁcation
pFastBAC vector encoding N-terminal hexahistidine-tagged
human ERK5 and HA-tagged human MEK5-DD (constitutively
active) were used to generate recombinant baculovirus using the
Bac-to-Bac system (Invitrogen). Spodoptera frugiperda 21 cells
(1.5106/ml) were infected at a multiplicity of infection of 6 with a
mix of both baculovirus and harvested 72 h post-infection. Pelleted
cells were lysed in ice-cold lysis buffer (50 mM Tris/HCl, pH 7.5,
1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM
sodium b-glycerophosphate, 50 mM NaF, 5 mM sodium pyro-
phosphate, 0.27 M sucrose, 1 mM benzamidine, 2 mM phenyl-
methanesulphonylﬂuoride (PMSF) and 1% Triton X-100), lysed in
one round of freeze/thawing, sonicated (4  20 s) and centrifuged
at 25,000 g for 30 min. His-tagged ERK5 was puriﬁed as described
for His-tagged BRSK1[33], using 5 mL Ni-NTA-agarose resin (Qia-
gen) followed by gel ﬁltration chromatography on Superdex 200HR
column on an AKTA system (GE Healthcare). Active ERK5 was pu-
riﬁed with yields ofw5 mg/L of infected cells, and was greater than
90% homogeneous as judged by densitometric scanning of Coo-
massie Blue-stained SDS/PAGE gels.
4.5. ERK5 kinase activity in vitro assay
Kinase activity was determined in an assay volume of 40 mL in
kinase buffer (50 mM TriseHCl, pH 7.5, 0.1 mM EGTA, 1 mM 2-
mercaptoethanol) containing 200 ng of pure active ERK5 and the
indicated amount of inhibitor. Reaction started by adding 10 mM
magnesium acetate, and 50 mM [g-32P]-ATP (500 cpm/pmol) and
250 mM PIMtide (ARKKRRHPSGPPTA) as substrates. Assays were
carried out for 20 min at 30 C, terminated by applying the reaction
mixture onto p81 paper and the incorporated radioactivity
measured as described previously [34].
4.6. Adaptor kinase assay of LRRK2 [G2019S]
In vitro kinase assays were conducted at Invitrogen (Madison,
WI) using the SelectScreen Kinase Proﬁling Service.
4.7. LRRK2 cellular assay
Reagents and general methods. Tissue-culture reagents were
from Life Technologies. Protein G Sepharose was from Amersham.
DNA constructs used for transfectionwere puriﬁed from Escherichia
coli DH5a using Qiagen or Invitrogen plasmid Maxi kits according
to the manufacturer’s protocol. All DNA constructs were veriﬁed by
DNA sequencing, which was performed by The Sequencing Service,
School of Life Sciences, University of Dundee, Scotland, U.K., using
DYEnamic ET terminator chemistry (Amersham Biosciences) on
Applied Biosystems automated DNA sequencers.
Cell culture, treatments and cell lysis. HEK293 was cultured in
DMEM (Dulbecco’s Modiﬁed Eagle’s medium) supplemented with
10% FBS (fetal bovine serum), 2 mM glutamine and 1 penicillin/
streptomycin solution. Lymphoblastoid cell lines were generated by
EBV (EpsteineBarr virus) transformation of B lymphocytes using
standard methods (European Collection of Cell Cultures). Cell-line
ANK is derived from a 47-year-old individual homozygous for the
LRRK2[G2019S] mutation who presented with Parkinson’s disease.
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mutation at the LRRK2 Gly2019 residue, and presented with no
disease. Human lymphoblastoid cells were maintained in RPMI
1640 with 10% FBS, 2 mM glutamine, 1 penicillin/streptomycin
solution and were maintained at cell density of 0.3  106e2  106
cells per mL. EpsteineBarr virus immortalized primary human
lymphoblastoid cells from one control subject and one Parkinson’s
disease patient homozygous for the LRRK2 [G2019S] mutationwere
kindly provided by Alastair Reith (GSK) and have been described
previously.25For inhibitor experiments, compounds were dissolved
in DMSO and utilized at the indicated concentrations. The con-
centration of DMSO in the culture media did not exceed 1%.
Following treatment, cells were washed once with phosphate
buffered saline (PBS) buffer and lysed with lysis buffer (50mM Tris/
HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate,
10 mM sodium b-glycerophosphate, 50 mM NaF, 5 mM sodium
pyrophosphate, 0.27 M sucrose, 1 mM benzamidine, 2 mM phe-
nylmethanesulphonylﬂuoride (PMSF) and 1% Triton X-100). When
not used immediately, all lysate supernatants were snap-frozen in
liquid nitrogen and stored at 80 C until use. Protein concentra-
tions were determined following centrifugation of the lysate at
16,000 g at 4 C for 20min using the Bradfordmethodwith BSA as
the standard. Transient transfection of HEK 293 cells was per-
formed using the polyethyleneimine (PEI) method [35].
4.8. Immunoblot procedures
Cell lysates from human lymphoblastoid cells and GFP-LRRK2
expressing stable cell lines were eluted in 65 ml 2 LDS sample
buffer (Invitrogen) with ﬁnal concentration of 1 mg/ml. Following
heating at 70 C for 10 min, 15 ml aliquots were resolved on 8% SDS
polyacrylamide gels and transferred to nitrocellulosemembranes for
detection of LRRK2 phosphorylated at Ser910, LRRK2 phosphory-
lated at Ser935 and total LRRK2, using puriﬁed rabbit monoclonal
antibodies (LRRK2 phospho-serine 910 clone, LRRK2 phospho-serine
935 clone and LRRK2 100-500 clone) in PBS with 0.1% sodium azide
(Epitomics). Immunoblot ﬁlms were scanned on an Epson 4990
scanner, and images were managed with Adobe Photoshop.
4.9. Molecular docking study
A molecular docking study to elucidate the interaction between
the inhibitors with the LRRK2 kinase domain was performed. First,
we constructed the homology model structure of the LRRK2 kinase
domain. We used a crystal structure of Roco kinase (PDB accession
code: 4F1T). Sequence alignment of LRRK2 and template proteins
was generated using the Discovery Studio 3.5 package (http://
www.accelrys.com). A 3D model structure of LRRK2 was built by
using the Modeller in Discovery Studio 3.5 package and was further
reﬁned by using the CHARMM force ﬁeld. Second, compounds 25
and 26 were built using Maestro build panel and minimized using
the Impact module of Maestro in the Schrödinger suite program.
The LRRK2 structure was minimized using the Protein Preparation
Wizard by applying an OPLS force ﬁeld. For the grid generation, the
binding site was deﬁned as the centroid of the ATP binding site.
Ligand docking into the active site of LRRK2 was carried out using
the Schrödinger docking program, Glide. The best-docked poses
were selected as the lowest Glide score. The molecular graphics for
the inhibitor binding pocket and reﬁned docking models were
generated using PyMol package (http://www.pymol.org).
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